On behalf of Sage shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and ...

Peter Hogendoorn, CEO and Executive Chairman of Sage Potash, commented: "We're thankful to Clark for his efforts as a director and wish him well." ...

Sage Therapeutics shares gained 0.4% to trade at $9.11 on Tuesday. These analysts made changes to their price targets on Sage Therapeutics following acquisition announcement.

Sage Therapeutics is a member of the Zacks Medical - Biomedical and Genetics industry. One other stock in the same industry, Compugen (CGEN), finished the last trading session 0.6% higher at $1.65.

Inland Empire residents stock up on supplies as imports expected to shrink Next week, incoming cargo volume to the U.S. from China is expected to drop, according to the Port of Los Angeles.

Sage Therapeutics (NASDAQ:SAGE) stock drops as Bank of America issues an Underperform rating citing an end to Biogen's (BIIB) recent buyout effort. Read more here.

We recently published a list of 10 Best Small-Cap Growth Stocks to Buy Now. In this article, we are going to take a look at where Sage Therapeutics, Inc.

"A prisoner’s incredible skills lead to the design of an iconic M1 Carbine rifle. Rated Red is your go-to channel for everything Heartland! From epic food and cars to military life, video games ...

The M1 Carbine is one of the most recognizable military firearms in the world. Here's an overview of how it works, and how you can own one today.

"A prisoner’s incredible skills lead to the design of an iconic M1 Carbine rifle. Rated Red is your go-to channel for everything Heartland! From epic food and cars to military life, video games ...

Sage Therapeutics Inc.’s stock fell 2% early Wednesday after the company said it would cease the development of a treatment for cognitive impairment associated with Huntington’s disease after ...

Get the latest stock analysis from Benzinga? This article After Series Of Trial Setbacks, Sage Therapeutics To Lay Off One-Third Workforce originally appeared on Benzinga.com ...